Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure
This is a phase II, open-label, single-arm clinical study of nimotuzumab in combination with immune checkpoint inhibitors in patients with advanced liver cancer who have failed first-line therapy
HCC
DRUG: Nimotuzumab|DRUG: ICIs(Immune checkpoint inhibitors)
ORR（Objtective reseponse rate）, （Objtective reseponse rate）, up to 24 month
OS（overall survival）, Time from the first dose to death, up to 24 month|PFS（pregression free survival）, time form fist dose to tumor progression or death, up to 24 month
This study is a prospective, single-arm study, and plans to include 30 patients with hepatocellular carcinoma who do not respond to first-line therapy with a protoPD-1 (or PD-L1) inhibitor in combination with nimotuzumab in the posterior line, and receive nimotuzumab 400mg, D1, QW in combination with PD-1 (or PD-L1) inhibitor in the later line of treatment until disease progression and intolerable toxicity